Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
Sponsor: Massachusetts General Hospital
This PHASE2 trial investigates Nonalcoholic Fatty Liver Disease (NAFLD) and is currently completed. Massachusetts General Hospital leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE2
Phase: NA → PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jun 2021 — Dec 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Feb 2021 — Jun 2021 [monthly]
Recruiting NA
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Mar 2020 — Jan 2021 [monthly]
Recruiting NA
-
Feb 2019 — Mar 2020 [monthly]
Recruiting NA
-
Jun 2018 — Feb 2019 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .